HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ALNY
Alnylam Pharmaceuticals Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $40.37B
Market Cap
$40.37B
Enterprise Val
$40.43B
P/E Ratio
128.66
P/B Ratio
51.15
Trailing PEG (1Y)
-0.41
As Of
Apr 23, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$789.2M
Gross Margin75.60%
Profit Margin75.60%
Return on Equity90.35%
Return on Assets6.75%
Current Ratio2.76
Debt/Equity3.76
LT Debt/Equity3.43
Revenue Per Share8.30

Income Statement

Dec 31, 2025
Revenue$1.10B
Cost of Revenue$267.7M
Gross Profit$829.3M
R&D$372.2M
SG&A$325.4M
Operating Expenses$697.6M
Operating Income$131.7M
Interest Expense$129.3M
Tax Expense-$25.3M
Net Income$186.4M
EPS (Basic)$1.41
EPS (Diluted)$1.38
EBIT$290.5M
EBITDA$304.0M
Consolidated Income$186.4M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$1.66B
Accounts Receivable$777.6M
Inventory$82.7M
Current Assets$4.05B
LT Investments$22.2M
Property, Plant & Equipment$708.1M
Intangibles$0.00
Non-Current Assets$915.7M
Total Assets$4.97B
Accounts Payable$115.7M
Current Debt$265.6M
Current Liabilities$1.47B
LT Debt$2.70B
Non-Current Liabilities$2.71B
Total Liabilities$4.18B
Total Debt$2.97B
Retained Earnings-$6.70B
Shareholder Equity$789.2M
Shares Outstanding132,113,818

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow$163.6M
Investing Cash Flow-$37.2M
Financing Cash Flow$45.3M
CapEx-$23.3M
Free Cash Flow$140.3M
Depreciation & Amort.$13.5M
Stock-Based Comp$71.6M
Acquisitions / Disposals$0.00
Investment Activity-$13.9M
Debt Issued/Repaid$3.6M
Equity Issued/Repaid$41.7M
Dividends Paid$0.00
Net Change in Cash$166.0M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h